ID   PDK3_HUMAN              Reviewed;         406 AA.
AC   Q15120; B4DXG6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-APR-2017, entry version 172.
DE   RecName: Full=[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial;
DE            EC=2.7.11.2;
DE   AltName: Full=Pyruvate dehydrogenase kinase isoform 3;
DE   Flags: Precursor;
GN   Name=PDK3; Synonyms=PDHK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7499431; DOI=10.1074/jbc.270.48.28989;
RA   Gudi R., Bowker-Kinley M.M., Kedishvili N.Y., Zhao Y., Popov K.M.;
RT   "Diversity of the pyruvate dehydrogenase kinase gene family in
RT   humans.";
RL   J. Biol. Chem. 270:28989-28994(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CATALYTIC ACTIVITY, FUNCTION, INTERACTION WITH DLAT, AND ENZYME
RP   REGULATION.
RX   PubMed=10748134; DOI=10.1074/jbc.M909488199;
RA   Baker J.C., Yan X., Peng T., Kasten S., Roche T.E.;
RT   "Marked differences between two isoforms of human pyruvate
RT   dehydrogenase kinase.";
RL   J. Biol. Chem. 275:15773-15781(2000).
RN   [6]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=11486000; DOI=10.1074/jbc.M103069200;
RA   Korotchkina L.G., Patel M.S.;
RT   "Site specificity of four pyruvate dehydrogenase kinase isoenzymes
RT   toward the three phosphorylation sites of human pyruvate
RT   dehydrogenase.";
RL   J. Biol. Chem. 276:37223-37229(2001).
RN   [7]
RP   INTERACTION WITH DLAT.
RX   PubMed=11978179; DOI=10.1042/BJ20020301;
RA   Tuganova A., Boulatnikov I., Popov K.M.;
RT   "Interaction between the individual isoenzymes of pyruvate
RT   dehydrogenase kinase and the inner lipoyl-bearing domain of
RT   transacetylase component of pyruvate dehydrogenase complex.";
RL   Biochem. J. 366:129-136(2002).
RN   [8]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=16436377; DOI=10.1074/jbc.M511481200;
RA   Korotchkina L.G., Sidhu S., Patel M.S.;
RT   "Characterization of testis-specific isoenzyme of human pyruvate
RT   dehydrogenase.";
RL   J. Biol. Chem. 281:9688-9696(2006).
RN   [9]
RP   INDUCTION BY PPARD.
RX   PubMed=17669420; DOI=10.1016/j.jmb.2007.06.091;
RA   Degenhardt T., Saramaki A., Malinen M., Rieck M., Vaisanen S.,
RA   Huotari A., Herzig K.H., Muller R., Carlberg C.;
RT   "Three members of the human pyruvate dehydrogenase kinase gene family
RT   are direct targets of the peroxisome proliferator-activated receptor
RT   beta/delta.";
RL   J. Mol. Biol. 372:341-355(2007).
RN   [10]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=18718909; DOI=10.1074/jbc.M803508200;
RA   Lu C.W., Lin S.C., Chen K.F., Lai Y.Y., Tsai S.J.;
RT   "Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible
RT   factor-1 promotes metabolic switch and drug resistance.";
RL   J. Biol. Chem. 283:28106-28114(2008).
RN   [11]
RP   INDUCTION.
RX   PubMed=20715114; DOI=10.1002/ijc.25599;
RA   Blouin J.M., Penot G., Collinet M., Nacfer M., Forest C.,
RA   Laurent-Puig P., Coumoul X., Barouki R., Benelli C., Bortoli S.;
RT   "Butyrate elicits a metabolic switch in human colon cancer cells by
RT   targeting the pyruvate dehydrogenase complex.";
RL   Int. J. Cancer 128:2591-2601(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   FUNCTION.
RX   PubMed=22865452; DOI=10.1158/0008-5472.CAN-12-0979;
RA   Kluza J., Corazao-Rozas P., Touil Y., Jendoubi M., Maire C.,
RA   Guerreschi P., Jonneaux A., Ballot C., Balayssac S., Valable S.,
RA   Corroyer-Dulmont A., Bernaudin M., Malet-Martino M., de Lassalle E.M.,
RA   Maboudou P., Formstecher P., Polakowska R., Mortier L., Marchetti P.;
RT   "Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma
RT   toward mitochondrial oxidative metabolism and potentiates the
RT   therapeutic activity of pro-oxidants.";
RL   Cancer Res. 72:5035-5047(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 9-406 IN COMPLEX WITH ATP,
RP   FUNCTION, AND INTERACTION WITH DLAT.
RX   PubMed=15861126; DOI=10.1038/sj.emboj.7600663;
RA   Kato M., Chuang J.L., Tso S.C., Wynn R.M., Chuang D.T.;
RT   "Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl
RT   domain 2 of human pyruvate dehydrogenase complex.";
RL   EMBO J. 24:1763-1774(2005).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 9-406, AND INTERACTION WITH
RP   DLAT.
RX   PubMed=17532006; DOI=10.1016/j.jmb.2007.04.083;
RA   Devedjiev Y., Steussy C.N., Vassylyev D.G.;
RT   "Crystal structure of an asymmetric complex of pyruvate dehydrogenase
RT   kinase 3 with lipoyl domain 2 and its biological implications.";
RL   J. Mol. Biol. 370:407-416(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 9-406 IN COMPLEX WITH THE
RP   INHIBITOR RADICICOL, FUNCTION, ENZYME REGULATION, AND INTERACTION WITH
RP   DLAT.
RX   PubMed=17683942; DOI=10.1016/j.str.2007.07.001;
RA   Kato M., Li J., Chuang J.L., Chuang D.T.;
RT   "Distinct structural mechanisms for inhibition of pyruvate
RT   dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and
RT   radicicol.";
RL   Structure 15:992-1004(2007).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-219.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19]
RP   VARIANT CMTX6 HIS-158, VARIANTS THR-114 AND SER-334, CHARACTERIZATION
RP   OF VARIANT CMTX6 HIS-158, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   ASN-120 AND ASP-121.
RX   PubMed=23297365; DOI=10.1093/hmg/dds557;
RA   Kennerson M.L., Yiu E.M., Chuang D.T., Kidambi A., Tso S.C., Ly C.,
RA   Chaudhry R., Drew A.P., Rance G., Delatycki M.B., Zuchner S.,
RA   Ryan M.M., Nicholson G.A.;
RT   "A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6)
RT   is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme
RT   3 (PDK3) gene.";
RL   Hum. Mol. Genet. 22:1404-1416(2013).
CC   -!- FUNCTION: Inhibits pyruvate dehydrogenase activity by
CC       phosphorylation of the E1 subunit PDHA1, and thereby regulates
CC       glucose metabolism and aerobic respiration. Can also phosphorylate
CC       PDHA2. Decreases glucose utilization and increases fat metabolism
CC       in response to prolonged fasting, and as adaptation to a high-fat
CC       diet. Plays a role in glucose homeostasis and in maintaining
CC       normal blood glucose levels in function of nutrient levels and
CC       under starvation. Plays a role in the generation of reactive
CC       oxygen species. {ECO:0000269|PubMed:10748134,
CC       ECO:0000269|PubMed:11486000, ECO:0000269|PubMed:15861126,
CC       ECO:0000269|PubMed:16436377, ECO:0000269|PubMed:17683942,
CC       ECO:0000269|PubMed:18718909, ECO:0000269|PubMed:22865452}.
CC   -!- CATALYTIC ACTIVITY: ATP + [pyruvate dehydrogenase (acetyl-
CC       transferring)] = ADP + [pyruvate dehydrogenase (acetyl-
CC       transferring)] phosphate. {ECO:0000269|PubMed:10748134,
CC       ECO:0000269|PubMed:11486000, ECO:0000269|PubMed:16436377}.
CC   -!- ENZYME REGULATION: Activated by interaction with DLAT. Inhibited
CC       by AZD7545, dichloroacetate and radicicol.
CC       {ECO:0000269|PubMed:10748134, ECO:0000269|PubMed:17683942}.
CC   -!- SUBUNIT: Homodimer. Interacts with the pyruvate dehydrogenase
CC       complex subunit DLAT, and is part of the multimeric pyruvate
CC       dehydrogenase complex that contains multiple copies of pyruvate
CC       dehydrogenase (E1), dihydrolipoamide acetyltransferase (DLAT, E2)
CC       and lipoamide dehydrogenase (DLD, E3).
CC       {ECO:0000269|PubMed:10748134, ECO:0000269|PubMed:11978179,
CC       ECO:0000269|PubMed:15861126, ECO:0000269|PubMed:17532006,
CC       ECO:0000269|PubMed:17683942}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15120-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15120-2; Sequence=VSP_043365;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, spinal
CC       cord, as well as fetal and adult brain.
CC       {ECO:0000269|PubMed:23297365}.
CC   -!- INDUCTION: Up-regulated in response to hypoxia. Up-regulated in
CC       response to fatty acids. Up-regulated by PPARD.
CC       {ECO:0000269|PubMed:17669420, ECO:0000269|PubMed:18718909,
CC       ECO:0000269|PubMed:20715114}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, X-linked dominant, 6 (CMTX6)
CC       [MIM:300905]: A form of Charcot-Marie-Tooth disease, a disorder of
CC       the peripheral nervous system, characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later
CC       of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies characterized by severely reduced motor nerve
CC       conduction velocities (NCVs) (less than 38m/s) and segmental
CC       demyelination and remyelination, and primary peripheral axonal
CC       neuropathies characterized by normal or mildly reduced NCVs and
CC       chronic axonal degeneration and regeneration on nerve biopsy.
CC       {ECO:0000269|PubMed:23297365}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PDK/BCKDK protein kinase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L42452; AAC42011.1; -; mRNA.
DR   EMBL; AK301965; BAG63378.1; -; mRNA.
DR   EMBL; CH471074; EAW99019.1; -; Genomic_DNA.
DR   EMBL; BC015948; AAH15948.1; -; mRNA.
DR   CCDS; CCDS14212.1; -. [Q15120-1]
DR   CCDS; CCDS48088.1; -. [Q15120-2]
DR   PIR; I70160; I70160.
DR   RefSeq; NP_001135858.1; NM_001142386.2. [Q15120-2]
DR   RefSeq; NP_005382.1; NM_005391.4. [Q15120-1]
DR   UniGene; Hs.296031; -.
DR   PDB; 1Y8N; X-ray; 2.60 A; A=9-406.
DR   PDB; 1Y8O; X-ray; 2.48 A; A=9-406.
DR   PDB; 1Y8P; X-ray; 2.63 A; A=9-406.
DR   PDB; 2PNR; X-ray; 2.50 A; A/B/E/F=9-406.
DR   PDB; 2Q8I; X-ray; 2.60 A; A=9-406.
DR   PDBsum; 1Y8N; -.
DR   PDBsum; 1Y8O; -.
DR   PDBsum; 1Y8P; -.
DR   PDBsum; 2PNR; -.
DR   PDBsum; 2Q8I; -.
DR   ProteinModelPortal; Q15120; -.
DR   SMR; Q15120; -.
DR   BioGrid; 111191; 35.
DR   DIP; DIP-29498N; -.
DR   IntAct; Q15120; 24.
DR   STRING; 9606.ENSP00000387536; -.
DR   BindingDB; Q15120; -.
DR   ChEMBL; CHEMBL3893; -.
DR   DrugBank; DB03760; Dihydrolipoic Acid.
DR   DrugBank; DB03758; Radicicol.
DR   GuidetoPHARMACOLOGY; 2143; -.
DR   iPTMnet; Q15120; -.
DR   PhosphoSitePlus; Q15120; -.
DR   BioMuta; PDK3; -.
DR   DMDM; 3183119; -.
DR   EPD; Q15120; -.
DR   MaxQB; Q15120; -.
DR   PaxDb; Q15120; -.
DR   PeptideAtlas; Q15120; -.
DR   PRIDE; Q15120; -.
DR   DNASU; 5165; -.
DR   Ensembl; ENST00000379162; ENSP00000368460; ENSG00000067992. [Q15120-1]
DR   Ensembl; ENST00000441463; ENSP00000387536; ENSG00000067992. [Q15120-2]
DR   GeneID; 5165; -.
DR   KEGG; hsa:5165; -.
DR   UCSC; uc004dbg.4; human. [Q15120-1]
DR   CTD; 5165; -.
DR   DisGeNET; 5165; -.
DR   GeneCards; PDK3; -.
DR   HGNC; HGNC:8811; PDK3.
DR   HPA; HPA046583; -.
DR   HPA; HPA072492; -.
DR   MalaCards; PDK3; -.
DR   MIM; 300905; phenotype.
DR   MIM; 300906; gene.
DR   neXtProt; NX_Q15120; -.
DR   OpenTargets; ENSG00000067992; -.
DR   Orphanet; 352675; X-linked Charcot-Marie-Tooth disease type 6.
DR   PharmGKB; PA33156; -.
DR   eggNOG; KOG0787; Eukaryota.
DR   eggNOG; COG0642; LUCA.
DR   GeneTree; ENSGT00550000074574; -.
DR   HOGENOM; HOG000164315; -.
DR   HOVERGEN; HBG000511; -.
DR   InParanoid; Q15120; -.
DR   KO; K00898; -.
DR   OMA; DPHVLDD; -.
DR   OrthoDB; EOG091G07DJ; -.
DR   PhylomeDB; Q15120; -.
DR   TreeFam; TF314918; -.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   SIGNOR; Q15120; -.
DR   ChiTaRS; PDK3; human.
DR   EvolutionaryTrace; Q15120; -.
DR   GeneWiki; PDK3; -.
DR   GenomeRNAi; 5165; -.
DR   PRO; PR:Q15120; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000067992; -.
DR   CleanEx; HS_PDK3; -.
DR   Genevisible; Q15120; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004740; F:pyruvate dehydrogenase (acetyl-transferring) kinase activity; IDA:UniProtKB.
DR   GO; GO:0071398; P:cellular response to fatty acid; IMP:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0097411; P:hypoxia-inducible factor-1alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010510; P:regulation of acetyl-CoA biosynthetic process from pyruvate; IMP:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IMP:UniProtKB.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:UniProtKB.
DR   Gene3D; 1.20.140.20; -; 1.
DR   Gene3D; 3.30.565.10; -; 1.
DR   InterPro; IPR018955; BCDHK/PDK_N.
DR   InterPro; IPR003594; HATPase_C.
DR   InterPro; IPR005467; His_kinase_dom.
DR   Pfam; PF10436; BCDHK_Adom3; 1.
DR   Pfam; PF02518; HATPase_c; 1.
DR   SMART; SM00387; HATPase_c; 1.
DR   SUPFAM; SSF55874; SSF55874; 1.
DR   SUPFAM; SSF69012; SSF69012; 1.
DR   PROSITE; PS50109; HIS_KIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Carbohydrate metabolism; Charcot-Marie-Tooth disease;
KW   Complete proteome; Disease mutation; Glucose metabolism; Kinase;
KW   Mitochondrion; Neurodegeneration; Neuropathy; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase;
KW   Transit peptide.
FT   TRANSIT       1      ?       Mitochondrion. {ECO:0000255}.
FT   CHAIN         ?    406       [Pyruvate dehydrogenase (acetyl-
FT                                transferring)] kinase isozyme 3,
FT                                mitochondrial.
FT                                /FTId=PRO_0000023443.
FT   DOMAIN      131    362       Histidine kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00107}.
FT   NP_BIND     247    254       ATP. {ECO:0000269|PubMed:15861126}.
FT   NP_BIND     306    307       ATP. {ECO:0000269|PubMed:15861126}.
FT   NP_BIND     323    328       ATP. {ECO:0000269|PubMed:15861126}.
FT   BINDING     287    287       ATP. {ECO:0000269|PubMed:15861126}.
FT   MOD_RES     211    211       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q15118}.
FT   MOD_RES     212    212       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q15118}.
FT   MOD_RES     278    278       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q922H2}.
FT   MOD_RES     374    374       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BFP9}.
FT   VAR_SEQ     406    406       Q -> QDKIKTNRTF (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043365.
FT   VARIANT     114    114       K -> T (in dbSNP:rs146331370).
FT                                {ECO:0000269|PubMed:23297365}.
FT                                /FTId=VAR_070081.
FT   VARIANT     158    158       R -> H (in CMTX6; gain of function;
FT                                results in a 5-fold increase in kinase
FT                                activity, decreased sensitivity to
FT                                pyruvate inhibition, reduced affinity for
FT                                nucleotides and increased affinity for
FT                                pyruvate dehydrogenase complex component
FT                                E2 (PDC-E2), leading to PDC
FT                                hyperphosphorylation and increased
FT                                inactivation; dbSNP:rs397515323).
FT                                {ECO:0000269|PubMed:23297365}.
FT                                /FTId=VAR_070082.
FT   VARIANT     219    219       E -> A (in a head & neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042297.
FT   VARIANT     334    334       Y -> S. {ECO:0000269|PubMed:23297365}.
FT                                /FTId=VAR_070083.
FT   MUTAGEN     120    120       N->H: No effect on kinase activity; when
FT                                associated with N-121.
FT                                {ECO:0000269|PubMed:23297365}.
FT   MUTAGEN     121    121       D->N: No effect on kinase activity; when
FT                                associated with H-120.
FT                                {ECO:0000269|PubMed:23297365}.
FT   HELIX        14     21       {ECO:0000244|PDB:1Y8O}.
FT   HELIX        29     38       {ECO:0000244|PDB:1Y8O}.
FT   HELIX        42     64       {ECO:0000244|PDB:1Y8O}.
FT   HELIX        69     72       {ECO:0000244|PDB:1Y8O}.
FT   HELIX        75     92       {ECO:0000244|PDB:1Y8O}.
FT   HELIX        93     96       {ECO:0000244|PDB:1Y8O}.
FT   STRAND       99    101       {ECO:0000244|PDB:2Q8I}.
FT   HELIX       102    118       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       119    121       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       122    137       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       141    172       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      179    184       {ECO:0000244|PDB:2PNR}.
FT   STRAND      187    192       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       193    212       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      218    224       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      233    236       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       238    260       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      262    265       {ECO:0000244|PDB:2PNR}.
FT   STRAND      270    276       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      278    287       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       294    297       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       298    301       {ECO:0000244|PDB:1Y8O}.
FT   TURN        303    305       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      323    325       {ECO:0000244|PDB:1Y8P}.
FT   HELIX       327    337       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      341    347       {ECO:0000244|PDB:1Y8O}.
FT   TURN        348    350       {ECO:0000244|PDB:1Y8O}.
FT   STRAND      351    360       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       362    364       {ECO:0000244|PDB:1Y8O}.
FT   HELIX       374    380       {ECO:0000244|PDB:1Y8O}.
SQ   SEQUENCE   406 AA;  46939 MW;  EF2415D3F9D8D61E CRC64;
     MRLFRWLLKQ PVPKQIERYS RFSPSPLSIK QFLDFGRDNA CEKTSYMFLR KELPVRLANT
     MREVNLLPDN LLNRPSVGLV QSWYMQSFLE LLEYENKSPE DPQVLDNFLQ VLIKVRNRHN
     DVVPTMAQGV IEYKEKFGFD PFISTNIQYF LDRFYTNRIS FRMLINQHTL LFGGDTNPVH
     PKHIGSIDPT CNVADVVKDA YETAKMLCEQ YYLVAPELEV EEFNAKAPDK PIQVVYVPSH
     LFHMLFELFK NSMRATVELY EDRKEGYPAV KTLVTLGKED LSIKISDLGG GVPLRKIDRL
     FNYMYSTAPR PSLEPTRAAP LAGFGYGLPI SRLYARYFQG DLKLYSMEGV GTDAVIYLKA
     LSSESFERLP VFNKSAWRHY KTTPEADDWS NPSSEPRDAS KYKAKQ
//
